Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087. Issue 2 (December 2015) - Chen, Robert; Armand, Phillippe; Fanale, Michelle; Ribrag, Vincent; Zinzani, Pier; Ricart, Alejandro; Thompson, Seth; Balakumaran, Arun; Molin, Daniel; Shipp, Margaret; Moskowitz, Craig